Related Experiment Video

Updated: Jun 26, 2026

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism
08:44

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism

Published on: October 17, 2025

Do we have a cure for tuberous sclerosis complex?

Peter B Crino1

  • 1Department of Neurology, PENN Epilepsy Center, University of Pennsylvania Medical Center Philadelphia, Pennsylvania, USA. peter.crino@uphs.upenn.edu

Epilepsy Currents
|January 8, 2009
PubMed

Insights

New mouse models for tuberous sclerosis complex (TSC) allow testing of therapies. Rapamycin treatment in these models prevented seizures and improved learning, offering hope for neurological symptom management in TSC patients.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder causing tumors and neurological issues.
  • Existing treatments for neurological manifestations of TSC are limited.
  • Novel mouse models offer a platform for preclinical research.

Purpose of the Study:

  • To evaluate the therapeutic potential of rapamycin for neurological symptoms in mouse models of TSC.
  • To investigate the efficacy of rapamycin in preventing seizures and improving cognitive function.

Main Methods:

  • Utilized newly developed mouse models that recapitulate key aspects of TSC.
  • Administered rapamycin to TSC model mice.
  • Assessed seizure frequency and performance in learning tasks.

Main Results:

  • Rapamycin administration significantly prevented seizures in TSC mouse models.
  • Treatment with rapamycin led to improvements in learning task performance.
  • These results demonstrate rapamycin's efficacy in ameliorating neurological deficits.

Conclusions:

  • Rapamycin shows promise as a therapeutic agent for neurological manifestations of TSC.
  • These findings support further clinical investigation of rapamycin for TSC patients with intractable seizures and cognitive disabilities.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.